Acute pulmonary embolism and systemic thrombolysis in the era of COVID-19 global pandemic 2020: a case series of seven patients admitted to a regional hospital in the French epidemic cluster

John Philippe1*, Elena-Mihaela Cordeanu2, Marie-Béatrice Leimbach1, Stéphane Greciano1, and Wael Younes1

1Department of Cardiology and Vascular Disease, Colmar Hospital, 39 Avenue de la Liberté, 68024 Colmar, France; and 2Department of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 1, place de l’Hôpital, 67091 Strasbourg Cedex, France

Received 15 May 2020; first decision 7 July 2020; accepted 24 November 2020

Background
The novel Coronavirus [named severe acute respiratory syndrome-related coronavirus 2 (SARS CoV-2)] was associated with the development of acute respiratory distress syndrome (ARDS), which required mechanical ventilation in a high percentage of critically ill patients. Recent studies have highlighted a state of hypercoagulability in patients with SARS-CoV-2, leading to an increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE). The low proportion of PE-associated to DVT in COVID-19 patients may suggest that they have pulmonary thrombosis rather than embolism. There is no guideline recommendation on the treatment of massive PE in COVID-19 patients suffering from ARDS, without cardiogenic shock.

Case summary
We described a series of seven SARS-COV-2 patients diagnosed with PE, in our institution, who underwent the use of systemic thrombolysis (recombinant tissue plasminogen activator) according to the standard protocol of 10mg over 15 min, then 90mg over 120 min.

Discussion
According to the European Society of Cardiology (ESC) severity scale, three patients had high-risk PE and four had intermediate high-risk PE. Systemic thrombolysis was found to be associated with a reduction of the Brescia-COVID Respiratory Severity Scale in five patients, recording a reduction from 3 to 1 in 2/5 patients, and from 3 to 2 in 3/5 patients. Furthermore, 3/5 patients had an initial improvement of their alveolar partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio ranging from a 19% (Patient 3) to a 156% improvement (Patient 6). It was also associated with a decrease of the right ventricular (RV) dysfunction and the RV/left ventricular ratio 24h later. No major bleeding events occurred after the thrombolysis, but the overall mortality after performing systemic thrombolysis was up to 3/7 patients.

Conclusion
Despite the low level of knowledge about the underlying pathophysiology of the COVID-19 ARDS, venous thromboembolic events, and the microvascular thrombosis, our findings suggest that in the treatment of PE with

* Corresponding author. Tel: +33 389124108, Fax: +33 389124136, Email: john.philippe@ch-colmar.fr
Handling Editor: Georg Goliasch
Peer-reviewers: F. Aaysha Cader; Kynakos Dimitriads and David Niederseer
Compliance Editor: Gemina Doolub
Supplementary Material Editor: Fabienne Vervaat
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
RV failure in patients with COVID-19 suffering from ARDS, without cardiogenic shock, systemic thrombolysis should be considered.

Keywords COVID-19 • Pulmonary embolism • Thrombolysis • Case report

Learning points
• The inability to identify and accurately manage pulmonary embolism (PE) in patients admitted with COVID-19 acute respiratory distress syndrome (ARDS), could worsen the short-term prognosis of these patients.
• Systemic thrombolysis may be considered in COVID-19 patients suffering from ARDS who develop PE with right ventricular failure without cardiogenic shock.
• Possible entanglement of pulmonary microvascular thrombosis in COVID-19-related ARDS.

Introduction
The 2020 world pandemic due to a novel Coronavirus [named severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2)], that started in Wuhan (China), was associated with the development of acute respiratory distress syndrome (ARDS) and required mechanical ventilation in a high percentage of critically ill patients. The pathophysiology of ARDS results from an acute systemic inflammation that leads to a cytokine storm. The increase in proinflammatory cytokines within the lung, leads to the recruitment of leucocytes, further propagating the local inflammatory response and conducting to an abnormal gas exchange.

Recent studies have highlighted the changes in blood coagulation of patients with SARS-CoV-2. This state of hypercoagulability leads to an increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE). The incidence of PE in COVID patients is not clearly established. Despite systematic thrombosis prophylaxis with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) according to the current guidelines. Some series have shown that the incidence of venous thromboembolic events in COVID-19 patients in intensive care unit (ICU) reached 27%.

Nevertheless, the low proportion of PE-associated with DVT in COVID-19 patients may suggest that they have pulmonary thrombosis rather than embolism.

We report a series of seven COVID-19 patients with PE in our institution that required the use of systemic thrombolysis, the molecule used was the recombinant tissue plasminogen activator (rtPA).

Case presentation
Patient 1
A 40-year-old man, with no medical history, was admitted to the Emergency Unit for dyspnoea. He described that he had suffered from a progressive dyspnoea on exertion followed by a flu-like syndrome during the previous 15 days.

On admission, the patient was found to have a body temperature of 38°C, an oxygen saturation of 75% in breathing ambient air, and a tachypnoea at 32 cycles/min.

In the situation of this severe dyspnoea situation, an oxygen therapy was started at 6 L/min and a blood test was performed.

The decision was made to start a systemic thrombolysis using rtPA according to the standard protocol of 10 mg over 15 min, then 90 mg over 120 min followed by UFH anticoagulation for at least 48 h. The patient’s clinical evolution was favourable with an improvement in his respiratory status and a decrease in his respiratory rate. The oxygen requirement was only 4 L/min 24 h post-thrombolysis.

Follow up: The oxygen requirement of the patient was decreased progressively and he was in breathing ambient air 48 h after thrombolysis. The patient was discharged from hospital on Day 6, under Rivaroxaban 15 mg twice a day and then at Day 22, Rivaroxaban 20 mg once a day for at least 6 months.

Patient 2
A 53-year-old woman, active smoker, with a history of dysthyroidism, was admitted to the Emergency Unit with chest pain and dyspnoea. She complained of having had a fever, a cough, and had suffered from myalgia and diarrhoea for the previous 15 days.

On admission, the patient was suffering from a lateral chest pain. On auscultation, crackles were audible up to the mid zone on both sides. Her oxygen saturation in breathing ambient air was up to 85%.

In the presence of lateral chest pain, a blood test and an electrocardiogram (ECG) were performed, that showed D-dimer >20 000 ng/mL, and a sinus tachycardia at 105 b.p.m., with s1q3T3 pattern, and T-wave inversions in the right precordial leads.
The S1Q3T3 pattern shows the presence of an S-wave in lead I (indicating a rightward shift of QRS axis) with Q-wave and T inversion in lead III (Figure 1).6

The major suspicion of PE led to a CTPA that confirmed the diagnosis and showed pulmonary lesions of COVID-19 infection. The patient was transferred to ICU, and a TTE was done on arrival. The echography showed an RV/LV ratio of 2, an abnormal septum motion with an elevation of the RV systolic pressure (RVSP) at 68 mmHg, atrial septal aneurysm with patent foramen ovale. Intravenous UFH was started with a target between 2 and 3 times the control activated partial thromboplastin time (aPTT).

Twenty-four hours later, the patient presented with respiratory distress and oxygen saturation of 85% under 15 L/min O2 with tachypnoea, but without haemodynamic failure.

### Timeline

**Patient 1**: Male, 40 years old  
Day 1: Flu-like symptoms.  
Day 15: Respiratory distress. Oxygen saturation of 75% in breathing ambient air. Diagnosis of pulmonary embolism (PE) and admission to intensive care unit (ICU).  
Day 16: Respiratory distress underlying non-invasive ventilation 70% FiO2 with tachypnoea and hypoxaemia without haemodynamic failure. Systemic thrombolysis.  
Day 17: Oxygen requirement was only 4 L/min 24 h after thrombolysis.  
Day 18: Ambient air.  
Day 21: Discharged from hospital.

**Patient 2**: Female, 53 years old  
Day 1: Fever, cough, myalgia, and diarrhoea.  
Day 15: Saturation at 85% in breathing ambient air. Diagnosis of PE and admission to ICU.  
Day 16: Respiratory distress with oxygen saturation of 85% under 15 L/min with tachypnoea, but no haemodynamic failure. Systemic thrombolysis.  
Day 18: Ambient air.  
Day 24: Discharged from hospital.

**Patient 3**: Male, 58 years old  
Day 1: Cough with fever.  
Day 21: Saturation at 94% in breathing ambient air. Diagnosis of PE and admission to ICU.  
Day 23: Respiratory distress, with oxygen saturation of 94% under 15 L/min and tachypnoea (45 cycles/min).  
Day 24: Oxygen requirement was only 4 L/min 24 h after thrombolysis.  
Day 35: Discharged from hospital.

**Patient 4**: Male, 67 years old  
Day 1: Non-producing cough, fever and a worsening dyspnoea.  
Day 10: SARS CoV-2 was detected by RT-PCR from nasopharynx. Acute respiratory distress syndrome (ARDS) that required mechanical ventilation and transfer to ICU.  
Day 23: Respiratory distress, tachypnoea, and circulatory collapse with cardiogenic shock. Diagnosis of PE.  
Day 24: Deceased.

**Patient 5**: Male, 66 years old  
Day 1: Flu-like symptoms.  
Day 30: Respiratory distress. Saturation at 78% in breathing air. Diagnosis of PE, systemic thrombolysis and admission to ICU.  
Day 32: Deceased.

**Patient 6**: Female, 38 years old  
Day 1: Medio-thoracic chest pain without irradiation, followed by a severe dyspnoea. Sudden cardiac arrest. PE diagnosis. Systemic thrombolysis.  
Day 3: Extubation.  
Day 12: Discharged from hospital.

**Patient 7**: Male, 68 years old  
Day 1: Respiratory distress. Oxygen saturation between 80% and 85% on ambient air. PCR-RT from nasopharynx was positive. Transferred to ICU with ARDS.  
Day 6: Respiratory distress, circulatory collapse with cardiogenic shock. Diagnosis of PE. Systemic thrombolysis.  
Day 8: Transferred to Strasbourg Regional Hospital.  
Day 12: Put under venoarterial extracorporeal membrane oxygenation.  
Day 19: Deceased.
A systemic thrombolysis was performed according to the standard protocol of 10 mg over 15 min, then 90 mg over 120 min.

**Follow-up**: Favourable clinical evolution and on breathing ambient air 48 h later. She was discharged from hospital on Day 9 under Rivaroxaban 15 mg twice a day and then at Day 22, Rivaroxaban 20 mg once a day for at least 6 months.

**Patient 3**

A 58-year-old man was admitted to the Emergency Unit with a cough and fever that had evolved over the previous 3 weeks.

The ECG showed a sinus tachycardia of 100 b.p.m., with a S1Q3T3 pattern.

A CTPA was performed and showed a massive PE with acute right heart signs, and pulmonary lesions of COVID-19 infection.

In this patient, the first SARS CoV-2 RT-PCR from nasopharynx was negative, but the second one 24 h later was positive. After the CTPA, an intravenous UFH was started with a target between 2 and 3 times the control aPTT, and the patient was transferred to ICU.

The TTE on arrival, showed an RV/LV ratio of 2, abnormal septum motion, RV dysfunction with an elevation of the RVSP at 60 mmHg. A thrombus was visible in the right pulmonary artery.

Two days after his admission to ICU, he presented with severe respiratory distress, an oxygen saturation of 94% under 15 L/min and a tachypnoea (45 cycles/min).

A systemic thrombolysis was started using rtPA according to the standard protocol of 10 mg over 15 min, then 90 mg over 120 min. After 24 h, the patient was under 4 L of oxygen per minute.

**Follow up**: Patient was discharged from hospital on Day 14 under Rivaroxaban 15 mg twice a day and then at Day 22, Rivaroxaban 20 mg once a day for at least 6 months. The TTE was controlled after 1 month and did not show any abnormalities.

**Patient 4**

A 67-year-old man with no medical history was admitted to the Emergency Unit.

He complained of a 10-day history of non-productive cough, fever, and a worsening dyspnoea.

SARS CoV-2 was detected by RT-PCR from nasopharynx.

Rapidly, the patient developed an ARDS, which required mechanical ventilation and transfer to ICU.

In ICU, the patient was under LMWH preventive thromboprophylaxis with Enoxaparine 8000 UI once a day. His clinical status was improving but 13 days after admission, he presented with severe dyspnoea, respiratory distress, tachypnoea, and circulatory collapse with cardiogenic shock.

The TEE showed an RV/LV ratio at 1.5, an abnormal septum motion, an RV dysfunction with no visible thrombus.
A CTPA was performed that showed the massive PE and pulmonary lesions of COVID-19 infection. A systemic thrombolysis was decided according to the standard protocol of 10 mg over 15 min, then 90 mg over 120 min.

Follow up: Despite the use of vasopressor drugs, and a discussion of venoarterial extracorporeal membrane oxygenation (ECMO) the patient died 24 h later.

**Patient 5**

A 65-year-old man, with a past medical history of epilepsy.

He complained of having had flu-like symptoms for the previous month, with an aggravation of the dyspnoea that led him to call the emergency unit. On arrival of the paramedical unit, the patient had an oxygen saturation of 78% in breathing air, with a tachypnoea of 40 cycles/min. The patient was put on oxygen and transported to the Emergency Unit. On admission, the patient was in respiratory distress, with an oxygen saturation of 97% under 15 L/min and tachypnoea (42 cycles/min) but no haemodynamic failure.

The ECG showed sinus tachycardia of 100 b.p.m., S1Q3T3 pattern, and incomplete right bundle branch block.

CTPA confirmed a massive PE and pulmonary lesions of COVID-19 infection (Figures 2 and 3).

The first SARS CoV-2 RT-PCR from nasopharynx was negative, but the second one 48 h later was positive.

The TTE showed an RV/LV ratio >4.5, an abnormal septum motion, an RV dysfunction with an elevation of the RVSP at 60 mmHg, and a thrombus in the right atrium.

In this context, the decision was made to start a systemic thrombolysis according to the standard protocol of 10 mg over 15 min, then 90 mg over 120 min and the patient was transferred to ICU.
| Characteristics                                      | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
|-----------------------------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Age (years)                                         | 40        | 53        | 58        | 67        | 66        | 38        | 68        |
| Sex                                                 | Male      | Female    | Male      | Male      | Male      | Female    | Male      |
| BMI (kg/m²)                                         | 28.36     | 32.01     | 25.51     | 24.16     | 31.5      | 30.8      | 23.11     |
| Medical history                                     | No background | Dysthyroidism, Active smoker | Appendicectomy | No background | Epilepsy | Post-traumatic PE, Paraplegic | Stroke, Patent foramen ovale |
| VTE background                                      | None      | None      | None      | None      | None      | None      | None      |
| VTE major provocation factor prior to admission     | None      | None      | None      | None      | None      | None      | None      |
| SARS-CoV2 pneumonia diagnosis                      | PCR Positive | SARS-CoV2 Positive | >75 | >75 | >75 | <25 | >75 |
| PE diagnostic delaya (days)                         | 15        | 15        | 21        | 23        | 28        | 15        | 20        |
| PE severityb                                        | Intermediate–high | Intermediate–high | Intermediate–high | High-risk | Intermediate–high | High-risk | High-risk |
| Anticoagulation prior to PE diagnosis               | None      | None      | None      | Preventive LMWH | None      | Preventive LMWH |
| BP at thrombolysis (mmHg)                           | 131/89    | 140/87    | 123/76    | 80/65     | 110/90    | Non-measurable | 75/55 |
| Symptoms requiring thrombolysis                     | Respiratory distress underlying non-invasive ventilation | Respiratory distress with saturation at 85% under 15 L/min O₂ | 2 days after admission in ICU, brutal respiratory distress, with saturation at 94% under 15 L/min, Tachyphoea (45 cycles/min) | No haemodynamic failure | Respiratory distress, saturation at 97% under 15 L/min, tachyphoea (42 cycles/min) | Non flow 0 min, Sudden cardiac arrest | 5 days after admission in ICU, respiratory distress, collapse with cardiogenic shock |
| Fibrinolytic agent                                  | rtPA 3    | rtPA 3    | rtPA 3    | rtPA 3    | rtPA 3    | rtPA 3    | rtPA 3    |
| Brescia-COVID Respiratory Severity Scalea before thrombolysis | 1         | 1         | 2         | NA        | 2         | NA        | 2         |
| Brescia-COVID Respiratory Severity Scale at H + 24 thrombolysis | 180       | 146       | 158       | 85        | 227       | 139       | 135       |
Table I  Continued

| Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
|-----------------|----------|-----------|-----------|-----------|-----------|-----------|-----------|
| PaO2/FiO2 at H + 24 thrombolysis | 271 | NA | 188 | NA | 198 | 357 | 125 |
| Haemoglobin (g/dL) before thrombolysis | 13.9 | 9.9 | 13.6 | 11.2 | 13.5 | 12.3 | 10.3 |
| Haemoglobin (g/dL) at H24 after thrombolysis | 10.8 | 9.7 | 12.4 | NA | 12.1 | 11.4 | 9.6 |
| D-dimer (ng/mL) | >20 000 | 2.352 | >20 000 | 15 000 | NA | NA | 702 |
| Troponin I at admission (ng/mL) | 0.084 | 2.5 | NA (HST I at 35) | <0.010 | NA (HST I at 346) | 0.060 | 0.013 |
| NT-proBNP at admission (ng/L) | 2630 | 4625 | 624 | 125 | 2104 | 2971 | 963 |
| Creatinin (micromole/L) | 78 | 91 | 93 | 65 | 120 | 71 | 87 |
| eGFR (mL/min/1.73m²) | 107 | 63 | 77 | 96 | NA | 54 | 93 |
| High-sensitivity C-reactive protein (mg/L) | 97 | 11 | 155 | 55 | 133 | 52 | 101 |
| Activated partial-thromboplastin time (s) | 31 | 30.3 | NA | 33 | 36.8 | 50 | 35.8 |
| Prothrombin time (%) | 91 | 85 | NA | 101 | 79 | 60 | 106 |
| Antiphospholipid antibodies | LupusAnticoagulant+ | Negative | Negative | Anti-β₂glycoprotein I antibodies | Anti-cardiolipin Ig antibodies | NA | Negative |

Echocardiography findings

| Before thrombolysis | RV/LV = 1.8 abnormal septum motion | RV/LV = 2 abnormal septum motion | RV/LV = 2 abnormal septum motion | RV/LV = 1.5 | RV/LV > 4.5 | RV/LV > 1.3 | RV/LV > 1 |
|---------------------|-----------------------------------|-----------------------------------|-----------------------------------|-------------|-------------|-------------|-------------|
| RV dysfunction      | RVSP = 68 mmHg                    | RV dysfunction                    | RVSP = 60 mmHg                    | Abnormal septum motion | RV dysfunction | Abnormal septum motion | McConnell sign |
| No thrombus         | ASA with PFO                      | No thrombus visualized            | RVSP = 60 mmHg                    | RVSP = 55 mmHg | RVSP = 60 mmHg | RVSP = 55 mmHg | Abnormal septum motion |
| visualized          |                                   |                                   | Thrombus in right pulmonary artery | RVSP = 55 mmHg | RVSP = 60 mmHg | RVSP = 55 mmHg | RVSP = 55 mmHg |
| After H + 24 thrombolysis | RV/LV < 1 | No RV dysfunction | RV/LV < 1 | No RV dysfunction | RV/LV = 1.5 | NA | NA |
| RVSP = 56 mmHg      | RVSP = 45 mmHg                    | RVSP = 50 mmHg                    | NA                               | RVSP = 50 mmHg | RVSP = 50 mmHg | RVSP = 50 mmHg | RVSP = 50 mmHg |

DVT

| Follow-up | Yes | Yes | No | NA | Yes | No | Yes |
|-----------|-----|-----|----|----|-----|----|-----|

Death

| Hospitalization length | 6 days | 9 days | 14 days | 15 days | 2 days | 11 days | 19 days |
|------------------------|--------|--------|---------|---------|--------|---------|---------|

Anticoagulation treatment at discharge

| Rivaroxaban | Rivaroxaban | Rivaroxaban | None | None | Rivaroxaban | None |

*Delay between the symptoms and the PE diagnosis.*

*According to ESC guidelines.*

*Brescia-COVID Respiratory Severity Scale.*

ASA, atrial septal aneurysm; BP, blood pressure; BMI, body mass index; CT, computerized tomography; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; kg, kilograms; FiO₂, inspired fraction of oxygen; HST I, high-sensitive Troponin I; ICU, intensive care unit; LMWH, low molecular weight heparin; LV, left ventricular; NA, not available; NT-pro BNP, N-terminal pro brain natriuretic peptide; PaO₂, alveolar partial pressure of oxygen; PCR, polymerase chain reaction; PE, pulmonary embolism; PFO, patent foramen ovale; RV, right ventricular; RVSP, right ventricular systolic pressure; sPESI, simplified pulmonary embolism severity index; SARS CoV-2, severe acute respiratory syndrome coronavirus 2; UFH, unfractionated heparin; VTE, venous thromboembolic events.
Follow-up: The patient presented a clinical improvement 24 h after the thrombolysis, but died 48 h later, from a refractory sudden cardiac arrest.

**Patient 6**
A 38-year-old woman, with a past medical history post-traumatic PE.
She complained of a medio-thoracic chest pain, followed by a severe dyspnea. On the arrival of the Emergency Unit, the patient was conscious but then had a sudden cardiac arrest, no-flow 0 min and low-flow 30 min. She was intubated, given cardiopulmonary resuscitation and transferred to the Emergency Room.
At arrival, the TTE found an RV dysfunction and a thrombus in the pulmonary arteries (Figures 4 and 5).
A CTPA scan confirmed the massive PE and showed pulmonary lesions of COVID-19.
A systemic thrombolysis was performed according to the standard protocol of 10 mg over 15 min, then 90 mg over 120 min and the patient was transferred to ICU.
Follow-up: A favourable clinical evolution and was extubated 2 days after.

The transthoracic cardiac echography was controlled 7 days after, showing no abnormalities.
She was discharged from hospital at Day 11, under Rivaroxaban 15 mg twice a day and then at Day 22, Rivaroxaban 20 mg once a day for at least 6 months.

**Patient 7**
A 68-year-old man, with a medical history of stroke, was admitted to the Emergency Unit with respiratory distress. The physical examination, found a tachypnoea, an oxygen saturation between 80% and 85% in ambient air and a body temperature of 38.5°C. In this dyspnoea situation, a blood test and a CT scan were performed.
The laboratory findings were a troponin at 0.013 ng/mL, D-dimer at 700 ng/mL, and a positive PCR-RT from nasopharynx.
The CT scan found diffuse pulmonary lesions of COVID-19.
The patient was transferred to ICU for ARDS. An antibiotherapy with Rovamyicine and Cefotaxime was started, and the patient was under LMWH preventive thromboprophylaxis with Enoxaparine 7000 UI once a day.
Five days after admission, he developed respiratory distress, circulatory collapse with cardiogenic shock.
The TTE showed an acute right dysfunction with RV/LV ratio >1, an abnormal septum motion and an RV dysfunction.
A systemic thrombolysis was decided according to the standard protocol of 10 mg over 15 min, then 90 mg over 120 min.
Follow-up: Though there was an improvement of echography criteria, the clinical state of the patient worsened. He was transferred to Strasbourg regional hospital and put on venoarterial ECMO. Unfortunately, the patient died after 7 days under ECMO.

**Results and discussion**
Our population was composed of 71% male, of an average age of 55 years, a mean body mass index of 27.9 kg/m², and none had major venous thromboembolic events provocation factors except the relative immobilization secondary to the COVID-19 disease. All the detailed characteristics appear in Table 1.

Patients were treated with systemic thrombolysis using rtPA according to the standard protocol of 10 mg over 15 min, then 90 mg over 120 min followed by UFH anticoagulation.

The current European Society of Cardiology (ESC) guidelines suggest the use of systemic thrombolysis in patients with high-risk PE, defined mainly by the presence of cardiogenic shock. In our case-series, 4/7 (57%) patients did not have cardiogenic shock but received primary reperfusion on the criteria of severe hypoxaemia and severe RV dysfunction.

Systemic thrombolysis was associated with a reduction of the Brescia-COVID Respiratory Severity Scale (BCRSS) in five patients, recording a reduction from 3 to 1 in 2/5 patients, and from 3 to 2 in 3/5 patients. The BCRSS is a stepwise management approach to COVID-19 patients based on bedside patient clinical severity. This scale was adopted and used to define objectively the patient’s response to treatment.

In addition, 60% (3/5) of the patients with available data had an initial improvement in their PaO₂/FiO₂ ratio ranging from a 19% improvement (Patient 3) to a 156% improvement (Patient 6). It was also associated with a decrease of the RV dysfunction and the RV/LV ratio at 24 h after thrombolysis.

No major bleeding events occurred after the thrombolysis. The overall mortality rate after systemic thrombolysis was 43% (3/7). Although no autopsies were performed, the main hypothesis is a death due to ARDS, and cytokine release syndrome.

(Patient 7 had improvement in echography criteria before dying and patient 5 had clinical improvement before the refractory cardiac arrest.)

Antiphospholipid antibodies were found in 2/5 patients (40%). However, the patients had no history of spontaneous venous thromboembolic events, and these antibodies can also arise transiently in patients with critical illness and various infections.

Moreover, in our study, COVID-19 patients have a marked elevation in measured C-reactive protein [average C-reactive protein (CRP) level of 86 mg/mL] and many assays to detect lupus anticoagulants are sensitive to the presence of CRP, resulting in false positive results.

In COVID-19 patients suffering from ARDS, the gas exchange is already limited and additional PE-related intrapulmonary shunting, alter the remaining exchange capacity. Thus, systemic thrombolysis may restore a part of the respiratory exchange capacity.

Moreover, a case series of three patients in whom fibrinolytic therapy was used led to a reduced mortality and marked improvements in oxygenation. In phase 1 clinical trial on pigs with induced ARDS, Hardaway et al. had shown a reduced mortality and marked improvements in oxygenation.

Two ongoing trials are investigating the efficacy of rtPA in COVID-19 related ARDS without PE based on the hypothesis of pulmonary microvascular thrombosis underlying ARDS.

More studies are needed to determine the benefit of the systemic thrombolysis for PE in patients with COVID-19, especially in the case of non-high-risk PE.

In our series, PE occurred after hospitalization in ICU and despite classic preventive anticoagulation in two patients. It was associated with the presence of a DVT in 66% (4/6 patients). Although of unproven benefit, it may suggest the need to increase the intensity of
thromboprophylaxis in the COVID-19 patients considering the microvascular thrombosis hypothesis. Due to a lack of recommendation in PE anticoagulation of COVID-19 patients, our hospital decided to treat them with oral anticoagulation by Rivaroxaban according to standard protocol (15 mg twice a day for 21 days then 20 mg once a day for at least 6 months).

Given the frequency of presentation of acute PE in COVID-19 patients, but also the risks associated with the injection of iodinated contrast medium, the place of CTPA in the evaluation of COVID-19 remains limited. A standardized diagnosis protocol incorporating CTPA for COVID-19 patients with respiratory distress would appear to be advisable, but more studies are needed to determine which COVID-19 patients require CTPA as a complement to the non-contrast CT scan.

**Conclusion**

The difficulty to identify and accurately manage PE in patients admitted with COVID-19 ARDS, could worsen the short-term prognosis of these patients.

Considering the possible entanglement of pulmonary microvascular thrombosis in COVID-19 related ARDS and despite the poor knowledge of its pathophysiology, our findings suggest that in COVID-19 patients suffering from ARDS who develop PE with RV failure without cardiogenic shock, systemic thrombosis may be considered. Larger studies are needed to explain the increased incidence of venous thromboembolic events in patients with COVID-19, to determine the appropriate prophylactic anticoagulation regimen and the benefit for rtPA therapy on respiratory and echographic criteria in patients with COVID-19. This study was reviewed and approved by the Ethical Committee of Strasbourg (CE-2020-124).

**Lead author biography**

John Philippe is the Medical doctor diploma in 2019, working as a junior doctor in a cardiology unit in Colmar, France. DIU of intensive care, heart failure, hypertension.

**Supplementary material**

Supplementary material is available at European Heart Journal - Case Reports online.

**Slide sets:** A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

**Consent:** The authors confirm that written consent for submission and publication of this case report including images and associated text has been obtained from the patients or patients’ next-of-kin in line with COPE guidance.

**Conflict of interest:** none declared.

**Funding:** none declared.

**References**

1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thorb Haemost 2020;18:844–847.
2. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bagnasco M, Bax N, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e415S–e495S.
3. Schünemann HJ, Cushman M, Bembom D, Kahn SR, Beyer-Westendorf J, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018;2:3198–3225.
4. Klok FA, Kruip MJHA, van de Meir NJM, Arbous MS, Gommers D, Kran KPH, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:148–150.
5. Poissy J, Goutay J, Caplan M, Parmentier E, Dubourg T, Lassalle F, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation 2020;142:184–186.
6. Petruzelli S, Palla A, Pieraccini F, Donnarumma V, Guinetti C. Routine electrocardiography in screening for pulmonary embolism. Respir Med 2018;135:150–156.
7. Konstantinides SV, Meyer G, Becattini C, Buono H, Geersing G-J, Harpola V-P, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543–603.
8. Duca A, Piva S, Focé E, Latronico N, Rizzi M. Calculated decisions: brescia-COVID respiratory severity scale (BCRSS)/algorithm. Emerg Med Pract 2020;22:CD1–CD2.
9. Piva S, Filippini M, Turfa F, Cattaneo S, Margola A, De Fulvio S, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. J Crit Care 2020;58:29–33.
10. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020;382:e38.
11. Connell NT, Battinelli EM, Connors JM. Coagulopathy of COVID-19 and antiphospholipid antibodies. J Thromb Haemost 2020. doi:10.1111/jth.14893.
12. Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Antithrombotic therapy in COVID-19: a final report on a prospective, non-randomized controlled trial with observational controls. J Thromb Haemost 2020;18:1752–1755.
13. Hardaway RM, Williams CH, Marvasti M, Farias M, Tseng A, Pinon I, et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 1990;18:1413–1418.
14. Hardaway RM, Harke H, Tyroch AH, Williams CH, Vazquez Y, Krause GF. Treatment of severe acute respiratory distress syndrome: a randomized controlled trial with observational controls. J Cardiopulm Vas Anesth 2020;34:433–445.
15. Revel MP, Parker AP, Prosch H, Silva M, Sverzellati N, Gleeson F, et al.; on behalf of the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). COVID-19 patients and the radiology department—advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging. Eur Radiol 2020;30:4903–4909.